Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Trial Profile

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2014

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zuretinol acetate (Primary)
  • Indications Age-related macular degeneration; Eye disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors QLT
  • Most Recent Events

    • 05 Dec 2014 Primary endpoint has not been met (low luminance low contrast best-corrected visual acuity [LLLC BCVA] measured at multiple time points), according to a QLT media release.
    • 05 Dec 2014 Results published in a QLT media release.
    • 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top